KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) EBITDA (2017 - 2025)

Historic EBITDA for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.

  • Co-Diagnostics' EBITDA rose 3864.97% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.5 million, marking a year-over-year increase of 2167.75%. This contributed to the annual value of -$37.4 million for FY2024, which is 532.13% down from last year.
  • As of Q3 2025, Co-Diagnostics' EBITDA stood at -$5.9 million, which was up 3864.97% from -$7.9 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' EBITDA registered a high of $13.6 million during Q3 2021, and its lowest value of -$21.6 million during Q4 2022.
  • Moreover, its 5-year median value for EBITDA was -$5.9 million (2023), whereas its average is -$3.3 million.
  • As far as peak fluctuations go, Co-Diagnostics' EBITDA skyrocketed by 105521.15% in 2021, and later plummeted by 33706.11% in 2023.
  • Quarter analysis of 5 years shows Co-Diagnostics' EBITDA stood at $10.3 million in 2021, then tumbled by 309.65% to -$21.6 million in 2022, then grew by 29.94% to -$15.1 million in 2023, then grew by 27.22% to -$11.0 million in 2024, then soared by 46.23% to -$5.9 million in 2025.
  • Its EBITDA stands at -$5.9 million for Q3 2025, versus -$7.9 million for Q2 2025 and -$7.6 million for Q1 2025.